Day: March 4, 2024

SABUGO, Portugal, March 04, 2024 (GLOBE NEWSWIRE) — Fusion Fuel (NASDAQ: HTOO) (the “Company”) announced today that it has received approval for a €1.015 million grant from the European Innovation Fund’s Horizon Europe Programme. The Company was included as a member of H2tALENT, a consortium of 29 partners from six countries across Europe and sponsored by the Universidade de Évora. H2tALENT was one of three consortia funded in the topic (HORIZON-JTI-CLEANH2-2023-1), which was created to develop small-scale hydrogen valleys that demonstrate the decarbonization potential of hydrogen and cover the entire value chain from research & development through to end-use. H2tALENT’s submission to the funding call, the Alentejo Hydrogen Valley, is aimed at bringing together pioneering initiatives and state-of-the-art technologies across...

Company announcement no. 9 2024  Group CommunicationsHolmens Kanal 2 – 12DK-1092 København KTel. +45 45 14 56 95 4 March 2024Danske Bank share buy-back programme: Transactions in week 9 On 2 February 2024, Danske Bank A/S announced a share buy-back programme for a total of DKK 5.5 billion, with a maximum of 70 million shares, in the period from 5 February 2024 to 31 January 2025, at the latest, as described in company announcement no. 2 2024. The programme is being carried out under Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016, also referred to as the Safe Harbour Rules. The following transactions were made under the share buy-back programme in week 9:  Number of shares VWAP DKK Gross valueDKKAccumulated,...

French limited company (Société anonyme) with registered capital of 106,945,095 eurosRegistered office: 14, rue Royale, 75008 Paris632 012 100 R.C.S. ParisLegal Entity Identifier: 529900JI1GG6F7RKVI53 Disclosure of total number of voting rights and number of sharesin the capital at January 31, 2024 Pursuant to article L-233-8 II of the French “Code de Commerce” and 223-16 of the AMF’s General Regulations:Total number of shares 534,725,475Number of real voting rights (excluding treasury shares) 534,725,475Theoretical number of voting rights (including treasury shares*)(*) pursuant to article 223-11 of the AMF’s General Regulations 534,725,475About L’Oréal For over 110 years, L’Oréal, the world’s leading beauty player, has devoted itself to one thing only: fulfilling the beauty aspirations of consumers around the...

Madrid, March 4 – South Korea has granted Spanish technology company Lleida.net (BME:LLN) (EPA:ALLLN) (OTCQX:LLEIF) its sixth patent in the country, this time for its electronic contract certification method. The recognition, granted by the Korean Intellectual Property Office (KIPO), is titled “Platform and Method for Certifying an Electronic Contract for Electronic Identification and Trust Services (EIDAS)” and is valid for 20 years. EIDAS is the European regulation that sets the standards for identification and trust services for electronic transactions within the EU. This technology generates the certification of the reception of electronic mail that contains a digital proof to demonstrate the reception, the content, the delivery and the non manipulation of the information and the message, valid before the courts and...

CARSON CITY, Nev., March 04, 2024 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of its best efforts public offering of 21,000,000 shares of its common stock (or pre-funded warrants (“Pre-funded Warrants”) in lieu thereof) and warrants to purchase up to 10,500,000 shares of common stock at a combined offering price of $1.00 per share (or Pre-funded Warrant) and associated warrant. The warrants will have an exercise price of $1.50 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance. The gross proceeds to the Company from the offering...

  Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s DiseaseVIVIAD Phase 2b study did not meet its primary and key secondary endpoints Varoglutamstat was generally well tolerated with low discontinuation rates due to adverse events and no evidence of symptomatic ARIAs in the clinical setting VIVIAD is a comprehensive, diligently designed and high-quality study; baseline demographics in the study were highly representative of early AD patient population Company is conducting an in-depth analysis of the results, including analyses of additional pre-specified and exploratory endpoints Further update expected to be provided no later than with publication of Company’s full year 2023 financial resultsHalle (Saale) / Munich, Germany, March 4, 2024 – Vivoryon Therapeutics N.V. (Euronext...

Saint-Herblain (France), March 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will participate at upcoming investor conferences in the United States and Europe. CEO Thomas Lingelbach will present Valneva at the TD Cowen 44th Annual Health Care Conference, taking place March 4 – 6, 2024, in Boston, MA. Mr. Lingelbach and CFO Peter Bühler will also meet with institutional investors during the Van Lanschot Kempen Life Sciences Conference, held April 16 – 17, 2024, in Amsterdam, The Netherlands. Management will discuss Valneva’s growing commercial business and pipeline of infectious disease vaccines. IXCHIQ®, Valneva’s third commercial product and the world’s first approved vaccine against chikungunya virus was recently recommended for use by the...

– Upfront cash payment of $170 million strengthens capital structure – – Transaction solidifies Coherus’ strategic focus in oncology – REDWOOD CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (NASDAQ: CHRS) today announced the completion of the previously announced divestiture of its CIMERLI® (ranibizumab-eqrn) ophthalmology franchise through the sale of its subsidiary, Coherus Ophthalmology LLC, to Sandoz, Inc. for upfront all-cash consideration of $170 million. This divestiture included Coherus’ CIMERLI biologics license application, ophthalmology sales and select field reimbursement teams, and access to proprietary commercial software. “This transaction sharpens the focus of our business as we advance our novel immuno-oncology pipeline and continue the launch of LOQTORZI™ in nasopharyngeal carcinoma...